rAAV9-hASAH1

N/A

Report date: 2025/01/26 16:24:11

Base Information

Drug NamerAAV9-hASAH1
Drug Alias NameAAV9-based ASAH1 gene therapy (Genethon/Universite Paris-Saclay/Medical College of Wisconsin)AAV9-based ASAH1 gene therapy (Genethon/Universite Paris-Saclay/Medical College of Wisconsin)ASAH1 gene therapy (Genethon/Universite Paris-Saclay/Medical College of Wisconsin)
ClassificationBiologics
Mechanisms of ActionAcid ceramidase stimulants
TargetsAcid ceramidase
Therapy Area/IndicationsLipidosesMuscular Atrophy, SpinalMyoclonic Epilepsies, Progressive
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesFrance
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesUniversité Paris-Saclay
China Registration ClassN/A

Develop Information

Active CompaniesUniversité Paris-SaclayGenethonThe Medical College Of Wisconsin Nonprofit
Inactive CompaniesN/A
Active IndicationsLipidosesMuscular Atrophy, SpinalMyoclonic Epilepsies, Progressive
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A